Chemotherapy and cerebrovascular disease

Basit Öğe Kaydı
dc.authoridCosar, Rusen/0000-0002-7953-8887
dc.authoridCosar, Rusen/0000-0002-7953-8887
dc.authorwosidCosar, Rusen/AAC-4045-2020
dc.authorwosidKocak, Zafer/AEG-7828-2022
dc.authorwosidCosar, Rusen/GQP-7875-2022
dc.contributor.authorSaynak, M.
dc.contributor.authorCosar-Alas, R.
dc.contributor.authorYurut-Caloglu, V.
dc.contributor.authorCaloglu, M.
dc.contributor.authorKocak, Z.
dc.contributor.authorUzal, C.
dc.date.accessioned2024-06-12T10:56:13Z
dc.date.available2024-06-12T10:56:13Z
dc.date.issued2008
dc.departmentTrakya Üniversitesien_US
dc.description.abstractCerebrovascular disease is common in cancer patients. Some tumors are at high risk for cerebrovascular complications. The development of cerebrovascular disease may be provoked by cancer treatment. No well-planned prospective studies about other causes of thrombosis are available, although various case reports about thrombosis related to chemotherapy have been published. L-asparaginase, cisplatin, 5-fluorouracil (5-FU) and methotrexate are anticancer agents which are reported to relate to stroke. The mechanisms by which antineoplastic agents may lead to stroke include endothelium toxicity and abnormalities of coagulation factors. Also, brain hemorrhages that could result from chemotherapy effects on the hemostatic system were reported. Besides, it is difficult to determine whether stroke is caused by chemotherapy or cancer itself Clinicians deal not only with problems originating from cancer itself but also with the complications resulting from its treatment. Treatment-induced cerebrovascular disorders affect quality of life and survival in cancer patients. For this reason, cancer treatment should be planned by taking into consideration the possibility of cerebrovascular complications.en_US
dc.identifier.endpage36en_US
dc.identifier.issn1107-0625
dc.identifier.issue1en_US
dc.identifier.pmid18404783en_US
dc.identifier.scopus2-s2.0-41549156479en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage31en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19702
dc.identifier.volume13en_US
dc.identifier.wosWOS:000256591700004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherZerbinis Medical Publen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChemotherapyen_US
dc.subjectCoagulopathyen_US
dc.subjectDisseminated Intravascular Coagulationen_US
dc.subjectEmbolismen_US
dc.subjectIntracranial Hemorrhageen_US
dc.subjectStrokeen_US
dc.subjectAcute Lymphoblastic-Leukemiaen_US
dc.subjectPrednisone-Vincristine Therapyen_US
dc.subjectCisplatin-Based Chemotherapyen_US
dc.subjectL-Asparaginase Therapyen_US
dc.subjectGerm-Cell Tumorsen_US
dc.subjectBreast-Canceren_US
dc.subjectMethotrexate Neurotoxicityen_US
dc.subjectVonwillebrand-Factoren_US
dc.subjectAdjuvant Treatmenten_US
dc.subjectIschemic Eventsen_US
dc.titleChemotherapy and cerebrovascular diseaseen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu